Search

Your search keyword '"Caravaggio F"' showing total 44 results

Search Constraints

Start Over You searched for: Author "Caravaggio F" Remove constraint Author: "Caravaggio F" Topic schizophrenia Remove constraint Topic: schizophrenia
44 results on '"Caravaggio F"'

Search Results

1. Decreased cortical gyrification and surface area in the left medial parietal cortex in patients with treatment-resistant and ultratreatment-resistant schizophrenia.

2. Impaired insight into illness is unrelated to subjective happiness, success, and life satisfaction in schizophrenia.

Catalog

Books, media, physical & digital resources

3. Dopaminergic dysfunction and excitatory/inhibitory imbalance in treatment-resistant schizophrenia and novel neuromodulatory treatment.

4. Decision tree classification of cognitive functions with D 2 receptor occupancy and illness severity in late-life schizophrenia.

5. Neuromelanin accumulation in patients with schizophrenia: A systematic review and meta-analysis.

6. Metformin for early comorbid glucose dysregulation and schizophrenia spectrum disorders: a pilot double-blind randomized clinical trial.

7. Exploring the relationship between impaired illness awareness and visuospatial inattention in patients with schizophrenia.

8. Dimensional distribution of cortical abnormality across antipsychotics treatment-resistant and responsive schizophrenia.

9. Apathy is not associated with reduced ventral striatal volume in patients with schizophrenia.

10. Insight and medication adherence in schizophrenia: An analysis of the CATIE trial.

11. Brain insulin action: Implications for the treatment of schizophrenia.

12. Glutamatergic neurometabolites and cortical thickness in treatment-resistant schizophrenia: Implications for glutamate-mediated excitotoxicity.

13. Neuroanatomical profiles of treatment-resistance in patients with schizophrenia spectrum disorders.

14. Assessing analytic and intuitive reasoning using the cognitive reflection test in young patients with schizophrenia.

15. Brain insulin action in schizophrenia: Something borrowed and something new.

16. Modulation of brain activity with transcranial direct current stimulation: Targeting regions implicated in impaired illness awareness in schizophrenia.

17. Alterations in body mass index and waist-to-hip ratio in never and minimally treated patients with psychosis: A systematic review and meta-analysis.

18. Glutamatergic Neurometabolite Levels in Patients With Ultra-Treatment-Resistant Schizophrenia: A Cross-Sectional 3T Proton Magnetic Resonance Spectroscopy Study.

19. The effects of illness severity, cognition, and estimated antipsychotic dopamine receptor occupancy on insight into the illness in schizophrenia: An analysis of clinical antipsychotic trials of intervention effectiveness (CATIE) data.

20. A meta-analysis of transcranial direct current stimulation for schizophrenia: "Is more better?"

21. The impact of delay in clozapine initiation on treatment outcomes in patients with treatment-resistant schizophrenia: A systematic review.

22. Expression of dopamine D2 and D3 receptors in the human retina revealed by positron emission tomography and targeted mass spectrometry.

23. The neural correlates of apathy in schizophrenia: An exploratory investigation.

24. Neurometabolite levels in antipsychotic-naïve/free patients with schizophrenia: A systematic review and meta-analysis of 1 H-MRS studies.

25. Striatal neurometabolite levels in patients with schizophrenia undergoing long-term antipsychotic treatment: A proton magnetic resonance spectroscopy and reliability study.

26. Amotivation is associated with smaller ventral striatum volumes in older patients with schizophrenia.

27. Intranasal oxytocin does not modulate jumping to conclusions in schizophrenia: Potential interactions with caudate volume and baseline social functioning.

28. Kynurenic Acid in Schizophrenia: A Systematic Review and Meta-analysis.

29. Impaired illness awareness and leftward visuospatial inattention in schizophrenia are attributable to a common neural deficit - Posterior parietal hemispheric imbalance.

30. Cognition and Dopamine D 2 Receptor Availability in the Striatum in Older Patients with Schizophrenia.

31. Threshold of Dopamine D2/3 Receptor Occupancy for Hyperprolactinemia in Older Patients With Schizophrenia.

32. Lack of association between dopaminergic antagonism and negative symptoms in schizophrenia: a positron emission tomography dopamine D2/3 receptor occupancy study.

33. Β-Amyloid Burden is Not Associated with Cognitive Impairment in Schizophrenia: A Systematic Review.

34. Dopamine D2/3 Receptor Occupancy Following Dose Reduction Is Predictable With Minimal Plasma Antipsychotic Concentrations: An Open-Label Clinical Trial.

35. Predicting Plasma Olanzapine Concentration Following a Change in Dosage: A Population Pharmacokinetic Study.

36. Reduced insulin-receptor mediated modulation of striatal dopamine release by basal insulin as a possible contributing factor to hyperdopaminergia in schizophrenia.

37. Effects of glutamate positive modulators on cognitive deficits in schizophrenia: a systematic review and meta-analysis of double-blind randomized controlled trials.

38. Examining endogenous dopamine in treated schizophrenia using [¹¹C]-(+)-PHNO positron emission tomography: A pilot study.

39. Evaluation of Antipsychotic Dose Reduction in Late-Life Schizophrenia: A Prospective Dopamine D2/3 Receptor Occupancy Study.

40. Neuroimaging findings in treatment-resistant schizophrenia: A systematic review: Lack of neuroimaging correlates of treatment-resistant schizophrenia.

41. Dopamine D₂/₃ receptor availability in the striatum of antipsychotic-free older patients with schizophrenia-A [¹¹C]-raclopride PET study.

42. Comparative efficacy between clozapine and other atypical antipsychotics on depressive symptoms in patients with schizophrenia: analysis of the CATIE phase 2E data.

43. The VAGUS insight into psychosis scale--self-report and clinician-rated versions.

44. Glutamate-mediated excitotoxicity in schizophrenia: a review.